Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 14/20 | 0.46 |
| ▸ | ACSS2 | Q9NR19 | 2/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | ECE1 | P42892 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3641237 | 0.91 | ACSS2 (0.38) | NR1H2ACSS2 | |
| SCHEMBL13560524 | 0.88 | ECE1 (0.38) | NR1H2ACSS2CYP1A2ECE1 | |
| SCHEMBL3033009 | 0.88 | NR1H2 (0.41) | NR1H2 | |
| SCHEMBL13560522 | 0.80 | ECE1 (0.36) | NR1H2ACSS2CYP1A2ECE1 | |
| SCHEMBL3641231 | 0.80 | KMT2A (0.41) | ACSS2 | |
| SCHEMBL13560523 | 0.77 | ACSS2 (0.36) | NR1H2ACSS2CYP1A2ECE1 | |
| SCHEMBL3027611 | 0.77 | NR1H2 (0.47) | NR1H2NR1H3GPR119 | |
| SCHEMBL22091341 | 0.74 | NR1H2 (0.64) | NR1H2NR1H3 | |
| SCHEMBL19013262 | 0.74 | CCR9 (0.51) | NR1H2NR1H3 | |
| SCHEMBL3033078 | 0.73 | CDK1 (0.42) | NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-26 | — | — | US | disclosed |
| EP-2166856-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008154271-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216746-A1 | CHEMICAL COMPOUNDS | SAMHD1, POLRMT, NUDT1 | NR1H2 1873/4885ACSS2 1466/4885NR1H3 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.